Skip to main content
Alexander Spira, MD, Oncology, Fairfax, VA, Inova Fair Oaks Hospital

AlexanderISpiraMD

Oncology Fairfax, VA

Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology, Sarcoma, Thoracic Cancer

Virginia Cancer Specialists

Dr. Spira is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Spira's full profile

Already have an account?

Education & Training

  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2000
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineClass of 1997

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2003 - 2024
  • MD State Medical License
    MD State Medical License 2000 - 2003
  • PA State Medical License
    PA State Medical License 1998 - 2000
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top Doctors:Washington DC Area Castle Connolly, 2012
  • Top Doctors:Washington-Baltimore Castle Connolly, 2012
  • Top MD Consumers Checkbook

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)  
    Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
  • Brigatinib Versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer  
    D Ross Camidge, Scott N Gettinger, Alexander Spira, The New England Journal of Medicine
  • Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR Inhibitor  
    Alexander I Spira, Helena A Yu, Clinical Lung Cancer

Abstracts/Posters

  • Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
    Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
    Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • The Impact of Immunotherapy on a Community Practice. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 2) 
    2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Authored Content

  • WCLC 2021: Study Improvements Mean Nothing Without PatientsFebruary 2021
  • Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018

Press Mentions

  • Advanced Soft Tissue Sarcomas: Dox + Olaratumab vs. Dox + PBO
    Advanced Soft Tissue Sarcomas: Dox + Olaratumab vs. Dox + PBOJune 1st, 2019
  • Insights on Tumor Growth Lead to New Treatments
    Insights on Tumor Growth Lead to New TreatmentsFebruary 24th, 2017
  • Virginia Cancer Specialists Receives Clinical Trials Research Award from Conquer Cancer Foundation
    Virginia Cancer Specialists Receives Clinical Trials Research Award from Conquer Cancer FoundationJuly 12th, 2016
  • Join now to see all

Professional Memberships

Hospital Affiliations